← back to search

Paul S. Giacomini

Montreal Neurological Institute and Hospital · CA
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Immunotherapy and Immune Responses, and T-cell and B-cell Immunology.
h-index
23
citations
1,968
works
76
NIH funding
primary concept
email

Recent publications

Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis
Neurology and Therapy 2025cited by 9position: middledoi
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis
JAMA Neurology 2024cited by 87position: middledoi
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
Proceedings of the National Academy of Sciences 2023cited by 58position: middledoi
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Multiple Sclerosis Journal 2022cited by 76position: middledoi
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Neurology 2020cited by 104position: middledoi
Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
Neurology Neuroimmunology & Neuroinflammation 2017cited by 78position: middledoi
Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis
The Journal of Immunology 2016cited by 122position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ayman Rezk · Hospital of the University of Pennsylvania2 papers (2016–2017)Frauke Zipp · Department of Physics, Mathematics and Informatics2 papers (2016–2017)Rui Li · Fujian University of Traditional Chinese Medicine2 papers (2016–2017)Stephen L. Hauser · University of California, San Francisco2 papers (2022–2025)Valentine Jehl · Novartis (Switzerland)2 papers (2022–2025)Sven G. Meuth · Antea Group (France)2 papers (2022–2025)Heinz Wiendl · JDSU (United States)2 papers (2022–2025)Jack P. Antel · Montreal Neurological Institute and Hospital2 papers (2016–2017)Felix Luessi · Johannes Gutenberg University Mainz2 papers (2016–2017)Amit Bar‐Or · University of California System2 papers (2016–2017)Anne H. Cross · Washington University in St. Louis1 papers (2022–2022)Ratnakar Pingili · Novartis (United States)1 papers (2022–2022)Roseanne Sullivan · McGill University Health Centre1 papers (2025–2025)Jing Xi · Shihezi University1 papers (2025–2025) · 1 papers (2025–2025)Morten Bagger · Novartis (Switzerland)1 papers (2022–2022)Bernd C. Kieseier · Novartis (Switzerland)1 papers (2022–2022) · 1 papers (2025–2025)Sibyl Wray · University of Tennessee at Knoxville1 papers (2025–2025)Ronald Zielman · Novartis (Switzerland)1 papers (2022–2022)